People · Operator
Named in public records as an officer, director or promoter · active 2018–2023 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tocagen Inc | — | Pharmaceuticals | Series C | $119.5M | $301.3M | 2023 |
| Forte Biosciences, Inc. | — | Biotechnology | Series B | $25.2M | $771.4M | 2018 |
Lawrence Eichenfield at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lawrence Eichenfield on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Wagner | 2 | 3 |
| Franklin M. Berger | 1 | 4 |
| Donald Williams | 1 | 4 |
| DAVID GRYSKA | 1 | 3 |
| Tuan Huynh | 1 | 2 |
| Faheem M. Hasnain | 1 | 2 |
| Dennis Berman | 1 | 2 |
| Lori R. Kunkel | 1 | 1 |
| Douglas Jolly | 1 | 1 |
| Harry Gruber | 1 | 1 |
| Antony Riley | 1 | 1 |
| Stephen Doberstein | 1 | 1 |
| Scott Brun | 1 | 1 |
| Hubert Chen | 1 | 1 |
| Steven Kornfeld | 1 | 1 |
| Barbara Fink | 1 | 1 |
| Mark J Foletta | 1 | 1 |
| Martin J Duvall | 1 | 1 |
| Antony A. Riley | 1 | 1 |
| Thomas Darcy | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.